PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
3803590-2	1987	We have investigated the binding of porcine, bovine, and equine PA2 to n-hexadecylphosphocholine (C16-PC) micelles using optically detected magnetic resonance (ODMR) spectroscopy.	miltefosine	71-96	LOC104974671	Bos taurus	64-67
3219357-5	1988	When phospholipase A2 binds to micelles of n-hexadecylphosphocholine, the amplitude of the fast ring rotation decreases.	miltefosine	43-68	phospholipase A2 group IB	Homo sapiens	5-21
3996599-1	1985	We have investigated the binding of porcine pancreatic phospholipase A2 (PA2) to n-hexadecylphosphocholine (C16PN) micelles using optical detection of triplet state magnetic resonance (ODMR) spectroscopy.	miltefosine	81-106	phospholipase A2 group IB	Homo sapiens	55-71
3444378-4	1987	One of these compounds, hexadecylphosphocholine (He-PC), which was 3H-labeled in the methyl-choline groups, showed a formation of labeled (diacyl)-phosphatidylcholine similar to that found with OM-GPC.	miltefosine	24-47	glycophorin C (Gerbich blood group)	Homo sapiens	197-200
3444378-4	1987	One of these compounds, hexadecylphosphocholine (He-PC), which was 3H-labeled in the methyl-choline groups, showed a formation of labeled (diacyl)-phosphatidylcholine similar to that found with OM-GPC.	miltefosine	49-54	glycophorin C (Gerbich blood group)	Homo sapiens	197-200
3996599-1	1985	We have investigated the binding of porcine pancreatic phospholipase A2 (PA2) to n-hexadecylphosphocholine (C16PN) micelles using optical detection of triplet state magnetic resonance (ODMR) spectroscopy.	miltefosine	81-106	phospholipase A2 group IB	Homo sapiens	73-76
32519337-9	2020	Recilisib-activated PI3K/Akt singling pathway could restrain apoptosis from inducing miR-23a-5p overexpression, and Miltefosine-blocked PI3K/Akt singling pathway could restrict apoptosis from inhibiting miR-23a-5p reduction.	miltefosine	116-127	thymoma viral proto-oncogene 1	Mus musculus	141-144
34012260-1	2021	Background: The purpose of this study was to investigate the suitability of nanostructured lipid carriers (NLCs) loaded with miltefosine (HePC) as an anticancer drug for the treatment of breast cancer.	miltefosine	125-136	hepcidin antimicrobial peptide	Mus musculus	138-142
33450054-5	2021	KEY RESULTS: The addition of miltefosine suppressed several eosinophilic effector reactions such as CD11b up-regulation, degranulation, chemotaxis and downstream signaling.	miltefosine	29-40	integrin subunit alpha M	Homo sapiens	100-105
33253864-0	2021	Association of Miltefosine with Granulocyte and Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Cutaneous Leishmaniasis in the Amazon Region: a randomized and controlled trial.	miltefosine	15-26	colony stimulating factor 2	Homo sapiens	32-84
33253864-0	2021	Association of Miltefosine with Granulocyte and Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Cutaneous Leishmaniasis in the Amazon Region: a randomized and controlled trial.	miltefosine	15-26	colony stimulating factor 2	Homo sapiens	86-92
33472938-2	2021	Previously, we and others have shown that the Akt inhibitor miltefosine inhibited virus entry.	miltefosine	60-71	AKT serine/threonine kinase 1	Homo sapiens	46-49
32894278-10	2021	The association of Miltefosine with GM-CSF do not improve therapeutic outcome.	miltefosine	19-30	colony stimulating factor 2	Homo sapiens	36-42
32833689-9	2020	Miltefosine reduced mast cell degranulation and TRPV1 activation, thereby reducing visceral hypersensitivity.	miltefosine	0-11	transient receptor potential cation channel subfamily V member 1	Homo sapiens	48-53
32410999-7	2020	APCs include miltefosine, perifosine, and erufosine, which represent the first-, second- and third generation of this class, respectively.	miltefosine	13-24	amyloid P component, serum	Homo sapiens	0-4
32851099-0	2020	Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis.	miltefosine	29-40	colony stimulating factor 2	Homo sapiens	65-71
32851099-6	2020	Proliferation of CD4+ T cells were enhanced in patients using miltefosine and in CD8+ T cells when GM-CSF was associated.	miltefosine	62-73	CD4 molecule	Homo sapiens	17-20
32508430-0	2020	Investigation of the in vitro cysticidal activity of miltefosine against Acanthamoeba spp.	miltefosine	53-64	histocompatibility minor 13	Homo sapiens	86-89
32508430-1	2020	The present study evaluated the in vitro efficacy of miltefosine against cysts of Acanthamoeba spp.	miltefosine	53-64	histocompatibility minor 13	Homo sapiens	95-98
32063363-9	2020	Miltefosine treatment also suppressed the TGFbeta1/Smad3 signaling pathway.	miltefosine	0-11	transforming growth factor, beta 1	Mus musculus	42-50
32063363-0	2020	Miltefosine suppression of Pten null T-ALL leukemia via beta-catenin degradation through inhibition of pT308-Akt and TGFbeta1/Smad3.	miltefosine	0-11	phosphatase and tensin homolog	Mus musculus	27-31
32063363-9	2020	Miltefosine treatment also suppressed the TGFbeta1/Smad3 signaling pathway.	miltefosine	0-11	SMAD family member 3	Mus musculus	51-56
32063363-0	2020	Miltefosine suppression of Pten null T-ALL leukemia via beta-catenin degradation through inhibition of pT308-Akt and TGFbeta1/Smad3.	miltefosine	0-11	catenin (cadherin associated protein), beta 1	Mus musculus	56-68
32063363-0	2020	Miltefosine suppression of Pten null T-ALL leukemia via beta-catenin degradation through inhibition of pT308-Akt and TGFbeta1/Smad3.	miltefosine	0-11	thymoma viral proto-oncogene 1	Mus musculus	109-112
32063363-0	2020	Miltefosine suppression of Pten null T-ALL leukemia via beta-catenin degradation through inhibition of pT308-Akt and TGFbeta1/Smad3.	miltefosine	0-11	transforming growth factor, beta 1	Mus musculus	117-125
32063363-12	2020	On the basis of the results, we conclude that Miltefosine can suppress leukemia by degrading beta-catenin through repression of the pT308-Akt and TGFbeta1/Smad3 signaling pathways.	miltefosine	46-57	catenin (cadherin associated protein), beta 1	Mus musculus	93-105
32063363-0	2020	Miltefosine suppression of Pten null T-ALL leukemia via beta-catenin degradation through inhibition of pT308-Akt and TGFbeta1/Smad3.	miltefosine	0-11	SMAD family member 3	Mus musculus	126-131
32063363-7	2020	Miltefosine (Hexadecylphosphocholine) is the first oral anti-Leishmania drug, which is a phospholipid agent and has been shown to inhibit the PI3K/Akt activity.	miltefosine	0-11	thymoma viral proto-oncogene 1	Mus musculus	147-150
32063363-7	2020	Miltefosine (Hexadecylphosphocholine) is the first oral anti-Leishmania drug, which is a phospholipid agent and has been shown to inhibit the PI3K/Akt activity.	miltefosine	13-36	thymoma viral proto-oncogene 1	Mus musculus	147-150
32063363-12	2020	On the basis of the results, we conclude that Miltefosine can suppress leukemia by degrading beta-catenin through repression of the pT308-Akt and TGFbeta1/Smad3 signaling pathways.	miltefosine	46-57	thymoma viral proto-oncogene 1	Mus musculus	138-141
32063363-8	2020	Treatment of the PtenDelta/Delta leukemic mice with Miltefosine for different durations demonstrated that the pT308-Akt and the beta-catenin expressions were inhibited in the leukemia blast cells.	miltefosine	52-63	thymoma viral proto-oncogene 1	Mus musculus	116-119
32063363-8	2020	Treatment of the PtenDelta/Delta leukemic mice with Miltefosine for different durations demonstrated that the pT308-Akt and the beta-catenin expressions were inhibited in the leukemia blast cells.	miltefosine	52-63	catenin (cadherin associated protein), beta 1	Mus musculus	128-140
32063363-12	2020	On the basis of the results, we conclude that Miltefosine can suppress leukemia by degrading beta-catenin through repression of the pT308-Akt and TGFbeta1/Smad3 signaling pathways.	miltefosine	46-57	transforming growth factor, beta 1	Mus musculus	146-154
32063363-12	2020	On the basis of the results, we conclude that Miltefosine can suppress leukemia by degrading beta-catenin through repression of the pT308-Akt and TGFbeta1/Smad3 signaling pathways.	miltefosine	46-57	SMAD family member 3	Mus musculus	155-160
31648908-4	2020	Additionally, treatment of infected mice with miltefosine as experimental control exhibited host defense allowing the restoration of CD11c+CD11b+ population and decrease in CD11c+CD8alpha+ subset.	miltefosine	46-57	integrin alpha X	Mus musculus	133-138
31998633-12	2019	Sustained responses lasting for 28 to 150 weeks were observed for cases with PIK3CA mutations treated with either miltefosine or everolimus and additional treatment with trametinib/dabrafenib in a case with BRAFV600E mutation.	miltefosine	114-125	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	77-83
31648908-4	2020	Additionally, treatment of infected mice with miltefosine as experimental control exhibited host defense allowing the restoration of CD11c+CD11b+ population and decrease in CD11c+CD8alpha+ subset.	miltefosine	46-57	integrin alpha M	Mus musculus	139-144
31648908-4	2020	Additionally, treatment of infected mice with miltefosine as experimental control exhibited host defense allowing the restoration of CD11c+CD11b+ population and decrease in CD11c+CD8alpha+ subset.	miltefosine	46-57	integrin alpha X	Mus musculus	173-178
31648908-4	2020	Additionally, treatment of infected mice with miltefosine as experimental control exhibited host defense allowing the restoration of CD11c+CD11b+ population and decrease in CD11c+CD8alpha+ subset.	miltefosine	46-57	CD8 antigen, alpha chain	Mus musculus	179-187
31648908-6	2020	L. donovani infection significantly induced OX40L expression and slightly downregulated SEMA 4A expression in CD11c+CD8alpha+ DCs whereas miltefosine treatment significantly downregulated OX40L expression along with pronounced upregulation of SEMA 4A expression in CD11c+CD11b+ DCs.	miltefosine	138-149	tumor necrosis factor (ligand) superfamily, member 4	Mus musculus	188-193
31648908-6	2020	L. donovani infection significantly induced OX40L expression and slightly downregulated SEMA 4A expression in CD11c+CD8alpha+ DCs whereas miltefosine treatment significantly downregulated OX40L expression along with pronounced upregulation of SEMA 4A expression in CD11c+CD11b+ DCs.	miltefosine	138-149	sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4A	Mus musculus	243-250
31648908-6	2020	L. donovani infection significantly induced OX40L expression and slightly downregulated SEMA 4A expression in CD11c+CD8alpha+ DCs whereas miltefosine treatment significantly downregulated OX40L expression along with pronounced upregulation of SEMA 4A expression in CD11c+CD11b+ DCs.	miltefosine	138-149	integrin alpha X	Mus musculus	265-270
31648908-6	2020	L. donovani infection significantly induced OX40L expression and slightly downregulated SEMA 4A expression in CD11c+CD8alpha+ DCs whereas miltefosine treatment significantly downregulated OX40L expression along with pronounced upregulation of SEMA 4A expression in CD11c+CD11b+ DCs.	miltefosine	138-149	integrin alpha M	Mus musculus	271-276
31648908-7	2020	SiRNA mediated knockdown of SEMA 4A markedly reduced CD11c+CD11b+ driven IFN-gamma, TNF-alpha and IL-12 synthesis in miltefosine treated mice whereas functional blocking of OX40L decreased CD11c+CD8alpha+ induced IL-10, IL-4 and TGF-beta synthesis in L. donovani infected group.	miltefosine	117-128	sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4A	Mus musculus	28-35
31648908-7	2020	SiRNA mediated knockdown of SEMA 4A markedly reduced CD11c+CD11b+ driven IFN-gamma, TNF-alpha and IL-12 synthesis in miltefosine treated mice whereas functional blocking of OX40L decreased CD11c+CD8alpha+ induced IL-10, IL-4 and TGF-beta synthesis in L. donovani infected group.	miltefosine	117-128	integrin alpha X	Mus musculus	53-58
31648908-7	2020	SiRNA mediated knockdown of SEMA 4A markedly reduced CD11c+CD11b+ driven IFN-gamma, TNF-alpha and IL-12 synthesis in miltefosine treated mice whereas functional blocking of OX40L decreased CD11c+CD8alpha+ induced IL-10, IL-4 and TGF-beta synthesis in L. donovani infected group.	miltefosine	117-128	integrin alpha M	Mus musculus	59-64
31737204-5	2019	Miltefosine, the inhibitor of PI3K/Akt, and dactolisib, the inhibitor of mTOR, abrogated recombinant LMO4-induced GC cell invasion and proliferation.	miltefosine	0-11	LIM domain only 4	Homo sapiens	101-105
32351209-6	2020	Results showed that the treatment using miltefosine, ICHQ or ICHQ/Mic induced significantly higher anti-parasite IFN-gamma, IL-12, GM-CSF, nitrite and IgG2a isotype antibody levels, which were associated with low IL-4 and IL-10 production.	miltefosine	40-51	interferon gamma	Mus musculus	113-122
32351209-6	2020	Results showed that the treatment using miltefosine, ICHQ or ICHQ/Mic induced significantly higher anti-parasite IFN-gamma, IL-12, GM-CSF, nitrite and IgG2a isotype antibody levels, which were associated with low IL-4 and IL-10 production.	miltefosine	40-51	colony stimulating factor 2 (granulocyte-macrophage)	Mus musculus	131-137
32351209-6	2020	Results showed that the treatment using miltefosine, ICHQ or ICHQ/Mic induced significantly higher anti-parasite IFN-gamma, IL-12, GM-CSF, nitrite and IgG2a isotype antibody levels, which were associated with low IL-4 and IL-10 production.	miltefosine	40-51	immunoglobulin heavy variable V1-9	Mus musculus	151-156
32351209-6	2020	Results showed that the treatment using miltefosine, ICHQ or ICHQ/Mic induced significantly higher anti-parasite IFN-gamma, IL-12, GM-CSF, nitrite and IgG2a isotype antibody levels, which were associated with low IL-4 and IL-10 production.	miltefosine	40-51	interleukin 4	Mus musculus	213-217
32351209-6	2020	Results showed that the treatment using miltefosine, ICHQ or ICHQ/Mic induced significantly higher anti-parasite IFN-gamma, IL-12, GM-CSF, nitrite and IgG2a isotype antibody levels, which were associated with low IL-4 and IL-10 production.	miltefosine	40-51	interleukin 10	Mus musculus	222-227
31473345-7	2019	When treated with the choline kinase inhibitor MN58b during the first 12 h, the lipids intensity inside ABCA3+ vesicles decreased, whereas intensity was unchanged when treated after 12 h. Miltefosine, a substrate of ABCA3, decreased the incorporation of labeled lipids in ABCA3+ vesicles at all time points.	miltefosine	188-199	ATP binding cassette subfamily A member 3	Homo sapiens	104-109
31473345-7	2019	When treated with the choline kinase inhibitor MN58b during the first 12 h, the lipids intensity inside ABCA3+ vesicles decreased, whereas intensity was unchanged when treated after 12 h. Miltefosine, a substrate of ABCA3, decreased the incorporation of labeled lipids in ABCA3+ vesicles at all time points.	miltefosine	188-199	ATP binding cassette subfamily A member 3	Homo sapiens	216-221
31473345-7	2019	When treated with the choline kinase inhibitor MN58b during the first 12 h, the lipids intensity inside ABCA3+ vesicles decreased, whereas intensity was unchanged when treated after 12 h. Miltefosine, a substrate of ABCA3, decreased the incorporation of labeled lipids in ABCA3+ vesicles at all time points.	miltefosine	188-199	ATP binding cassette subfamily A member 3	Homo sapiens	216-221
31087522-0	2019	Iron superoxide dismutase contributes to miltefosine resistance in Leishmania donovani.	miltefosine	41-52	iron superoxide dismutase	Leishmania donovani	0-25
31265827-8	2019	Here we suggest a putative mechanism underlying the effect of miltefosine on sphingosine kinase 1, involving miltefosine-induced inhibition of protein kinase C. In conclusion, our findings provide a possibility for treatment of lung cancer cells with lower concentrations of the two antitumor drugs, DMS and miltefosine, which is favorable, regarding their potential cytotoxicity to normal cells.	miltefosine	62-73	sphingosine kinase 1	Homo sapiens	77-97
31265827-8	2019	Here we suggest a putative mechanism underlying the effect of miltefosine on sphingosine kinase 1, involving miltefosine-induced inhibition of protein kinase C. In conclusion, our findings provide a possibility for treatment of lung cancer cells with lower concentrations of the two antitumor drugs, DMS and miltefosine, which is favorable, regarding their potential cytotoxicity to normal cells.	miltefosine	109-120	sphingosine kinase 1	Homo sapiens	77-97
31265827-8	2019	Here we suggest a putative mechanism underlying the effect of miltefosine on sphingosine kinase 1, involving miltefosine-induced inhibition of protein kinase C. In conclusion, our findings provide a possibility for treatment of lung cancer cells with lower concentrations of the two antitumor drugs, DMS and miltefosine, which is favorable, regarding their potential cytotoxicity to normal cells.	miltefosine	109-120	sphingosine kinase 1	Homo sapiens	77-97
31048243-3	2019	We studied the encapsulation of the amphiphilic compound miltefosine (HePC) into polymeric micelles of Pluronics F108, F68, F127, L44, and L64.	miltefosine	57-68	hepcidin antimicrobial peptide	Homo sapiens	70-74
31131539-9	2019	Also, PI3K inhibitor (Miltefosine) and mTOR inhibitor (rapamycin) were used to inhibit PI3K/Akt pathway.	miltefosine	22-33	AKT serine/threonine kinase 1	Rattus norvegicus	92-95
31366948-0	2019	Miltefosine increases macrophage cholesterol release and inhibits NLRP3-inflammasome assembly and IL-1beta release.	miltefosine	0-11	NLR family pyrin domain containing 3	Homo sapiens	66-71
31366948-0	2019	Miltefosine increases macrophage cholesterol release and inhibits NLRP3-inflammasome assembly and IL-1beta release.	miltefosine	0-11	interleukin 1 alpha	Homo sapiens	98-106
31366948-6	2019	Miltefosine treated cells showed marked increased in phosphorylation of kinases involved in autophagy induction such as; Adenosine monophosphate-activated protein kinase (AMPK) and Unc-51 like autophagy activating kinase (ULK1).	miltefosine	0-11	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	121-169
31366948-6	2019	Miltefosine treated cells showed marked increased in phosphorylation of kinases involved in autophagy induction such as; Adenosine monophosphate-activated protein kinase (AMPK) and Unc-51 like autophagy activating kinase (ULK1).	miltefosine	0-11	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	171-175
31366948-6	2019	Miltefosine treated cells showed marked increased in phosphorylation of kinases involved in autophagy induction such as; Adenosine monophosphate-activated protein kinase (AMPK) and Unc-51 like autophagy activating kinase (ULK1).	miltefosine	0-11	unc-51 like autophagy activating kinase 1	Homo sapiens	222-226
31366948-7	2019	The Toll like receptor (TLR) signaling pathway was blunted by Miltefosine treatment, resulting in decreased TLR4 recruitment to cell-surface and ~75% reduction in LPS induced pro-IL-1beta mRNA levels.	miltefosine	62-73	toll like receptor 4	Homo sapiens	108-112
31366948-7	2019	The Toll like receptor (TLR) signaling pathway was blunted by Miltefosine treatment, resulting in decreased TLR4 recruitment to cell-surface and ~75% reduction in LPS induced pro-IL-1beta mRNA levels.	miltefosine	62-73	interleukin 1 alpha	Homo sapiens	179-187
31366948-9	2019	Miltefosine treatment induced mitophagy and dampened NLRP3 inflammasome assembly.	miltefosine	0-11	NLR family pyrin domain containing 3	Homo sapiens	53-58
31366948-10	2019	Collectively, our data shows that Miltefosine induced ABCA1 mediated cholesterol release, induced AMPK phosphorylation and mitophagy, while dampening NLRP3 inflammasome assembly and IL-1beta release.	miltefosine	34-45	ATP binding cassette subfamily A member 1	Homo sapiens	54-59
31366948-10	2019	Collectively, our data shows that Miltefosine induced ABCA1 mediated cholesterol release, induced AMPK phosphorylation and mitophagy, while dampening NLRP3 inflammasome assembly and IL-1beta release.	miltefosine	34-45	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	98-102
31366948-10	2019	Collectively, our data shows that Miltefosine induced ABCA1 mediated cholesterol release, induced AMPK phosphorylation and mitophagy, while dampening NLRP3 inflammasome assembly and IL-1beta release.	miltefosine	34-45	NLR family pyrin domain containing 3	Homo sapiens	150-155
31366948-10	2019	Collectively, our data shows that Miltefosine induced ABCA1 mediated cholesterol release, induced AMPK phosphorylation and mitophagy, while dampening NLRP3 inflammasome assembly and IL-1beta release.	miltefosine	34-45	interleukin 1 alpha	Homo sapiens	182-190
30782984-3	2019	Thirteen of the synthesized compounds showed a significant antileishmanial activity, with 50% effective concentration (EC50) values lower than that for the reference drug miltefosine (EC50, 2.84 muM).	miltefosine	171-182	latexin	Homo sapiens	195-198
31036692-8	2019	Our findings suggest that miltefosine-induced activation of Th1 cytokines, particularly represented by increased gamma interferon (IFN-gamma) and interleukin 12 (IL-12), is essential to prevail over the Leishmania-driven Th2 response.	miltefosine	26-37	interferon gamma	Homo sapiens	113-140
31467355-9	2019	In addition, miltefosine reduced the effect of TRPV1 activation in TRPV1-transfected cells and prevented TRPV1-dependent visceral hypersensitivity induced by intracolonic-capsaicin in rat.	miltefosine	13-24	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	47-52
31467355-9	2019	In addition, miltefosine reduced the effect of TRPV1 activation in TRPV1-transfected cells and prevented TRPV1-dependent visceral hypersensitivity induced by intracolonic-capsaicin in rat.	miltefosine	13-24	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	67-72
31467355-9	2019	In addition, miltefosine reduced the effect of TRPV1 activation in TRPV1-transfected cells and prevented TRPV1-dependent visceral hypersensitivity induced by intracolonic-capsaicin in rat.	miltefosine	13-24	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	67-72
31113953-5	2019	Pharmacologic alteration of cellular phosphoinositide content with miltefosine reduces ZFYVE21 induction, EC activation, and allograft vasculopathy in a humanized mouse model.	miltefosine	67-78	zinc finger, FYVE domain containing 21	Mus musculus	87-94
29733808-8	2018	The miltefosine- and ketoconazole-loaded nanoniosomes inhibited the growth of promastigote and amastigote forms of Leishmania major in vitro after 48 h of incubation and had IC50 values of 53.39 +- 0.02 and 86.38 +- 0.07 mug mL-1, respectively.	miltefosine	4-15	L1 cell adhesion molecule	Mus musculus	225-229
30297367-0	2018	Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.	miltefosine	39-50	lipase precursor-like protein	Leishmania donovani	0-29
30297367-4	2018	In the present study, we assessed the role of the lipase precursor-like protein (Lip) in conferring tolerance to miltefosine by episomally overexpressing Lip in Leishmania donovani (LdLip++).	miltefosine	113-124	lipase precursor-like protein	Leishmania donovani	50-79
29993167-2	2018	In these studies, we tested the hypothesis that like in cancer cells, miltefosine"s efficacy in leishmaniasis is due to its inhibition of Akt activation in host cells.	miltefosine	70-81	AKT serine/threonine kinase 1	Homo sapiens	138-141
29993167-3	2018	We show using pharmacologic agents that block Akt activation by different mechanisms and also using an inducible knockdown approach that miltefosine loses its efficacy when its access to Akt1 is limited.	miltefosine	137-148	AKT serine/threonine kinase 1	Homo sapiens	46-49
29993167-3	2018	We show using pharmacologic agents that block Akt activation by different mechanisms and also using an inducible knockdown approach that miltefosine loses its efficacy when its access to Akt1 is limited.	miltefosine	137-148	AKT serine/threonine kinase 1	Homo sapiens	187-191
29993167-6	2018	Taken together, we propose that the acquisition of PI(4) P and the display of PI (3,4)P2 on LPVMs initiate the machinery that supports continuous Akt activation and sensitivity to miltefosine.	miltefosine	180-191	AKT serine/threonine kinase 1	Homo sapiens	146-149
28059524-4	2017	Combination treatment of 6j with a subcurative dose of miltefosine (5 mg/kg) in BALB/c mice almost completely ameliorated the disease (>97% inhibition) by augmenting nitric oxide generation and shifting the immune response toward Th1.	miltefosine	55-66	negative elongation factor complex member C/D, Th1l	Mus musculus	233-236
29321326-5	2018	The Akt inhibitor miltefosine inhibited the entry of McKrae but not the gKDelta31-68 mutant into SK-N-SH cells.	miltefosine	18-29	AKT serine/threonine kinase 1	Homo sapiens	4-7
26723251-4	2016	The wild type mice were also treated with celecoxib or a combination of celecoxib and a Akt specific inhibitor, miltefosine (MTF).	miltefosine	112-123	thymoma viral proto-oncogene 1	Mus musculus	88-91
27622989-9	2016	Similarly, this combination has likely shown a slight augmentation (p = 0.057) of miltefosine (2.5 muM) leishmanicidal efficacy on amastigote stage of the parasite in infected human macrophages by reducing their intracellular growth.	miltefosine	82-93	latexin	Homo sapiens	99-102
26299343-1	2015	In this investigation, Hexadecylphosphocholine (HePC, miltefosine) was being used as a new ingredient in Pegylated liposomal doxorubicin (PLD) and different aspects of this integration such as its effect on doxorubicin (Dox) release and cell uptake, cytotoxicity of liposomes, in vivo distribution and half-life clearance time of Dox as well as median survival time were illustrated.	miltefosine	23-46	hepcidin antimicrobial peptide	Mus musculus	48-52
26299343-1	2015	In this investigation, Hexadecylphosphocholine (HePC, miltefosine) was being used as a new ingredient in Pegylated liposomal doxorubicin (PLD) and different aspects of this integration such as its effect on doxorubicin (Dox) release and cell uptake, cytotoxicity of liposomes, in vivo distribution and half-life clearance time of Dox as well as median survival time were illustrated.	miltefosine	54-65	hepcidin antimicrobial peptide	Mus musculus	48-52
26744591-4	2015	With the addition of miltefosine, the patient no longer presented with bone marrow amastigotes, and displayed an increased CD4 count and negative Leishmania polymerase chain reaction results.	miltefosine	21-32	CD4 molecule	Homo sapiens	123-126
25980013-6	2015	We observed that compared with wild-type macrophages, the PAF receptor-deficient macrophages showed 1) reduced binding of a fluorescent analog of HPC, 2) decreased TNF-alpha production, and 3) lower miltefosine-induced killing of L. donovani.	miltefosine	199-210	platelet-activating factor receptor	Mus musculus	58-70
26119043-0	2015	Leptin augments protective immune responses in murine macrophages and enhances potential of miltefosine against experimental visceral leishmaniasis.	miltefosine	92-103	leptin	Mus musculus	0-6
26119043-3	2015	In the present study, we explored the in vitro immunomodulatory potential of an immunomodulator, leptin with lower concentration of standard drug, miltefosine.	miltefosine	147-158	leptin	Mus musculus	97-103
26119043-8	2015	Leptin plus miltefosine also induces the phagocytic ability (**p<0.01) of macrophages in comparison to leptin alone and miltefosine alone treated groups.	miltefosine	123-134	leptin	Mus musculus	0-6
26119043-9	2015	These finding illustrate that leptin activates host macrophages to generate protective immune response for the successful elimination of Leishmania parasite at lower concentration of miltefosine and has potential for further exploration in experimental animal model of visceral leishmaniasis (VL).	miltefosine	183-194	leptin	Mus musculus	30-36
25980013-7	2015	Miltefosine exhibited significantly compromised leishmanicidal function in PAF receptor-deficient mice.	miltefosine	0-11	platelet-activating factor receptor	Mus musculus	75-87
25980013-8	2015	An anti-PAF receptor Ab led to a significant decrease in miltefosine-induced intracellular Leishmania killing and IFN-gamma production in a macrophage-T cell coculture system.	miltefosine	57-68	platelet-activating factor receptor	Mus musculus	8-20
27490031-4	2015	Miltefosine inhibits PKCalpha competitively with regard to PS and non-competitively with regard to Ca(2+) , however, the mechanism of action is unknown.	miltefosine	0-11	protein kinase C alpha	Homo sapiens	21-29
26024228-9	2015	Both antileishmanial drugs reduced the parasite load of macrophages; miltefosine also suppressed IL-10 and IL-13 secretion in a dose dependent manner.	miltefosine	69-80	interleukin 10	Homo sapiens	97-102
26024228-9	2015	Both antileishmanial drugs reduced the parasite load of macrophages; miltefosine also suppressed IL-10 and IL-13 secretion in a dose dependent manner.	miltefosine	69-80	interleukin 13	Homo sapiens	107-112
26024228-13	2015	IL-13 increased in response to CpG plus miltefosine.	miltefosine	40-51	interleukin 13	Homo sapiens	0-5
24643019-9	2014	Interactions between these two compounds and miltefosine were classified as synergistic, with the most effective association being between AB13 and miltefosine, where decreases of IC50 values to 6 microM were observed, similar to the miltefosine activity alone.	miltefosine	45-56	NBPF member 1	Homo sapiens	139-143
24952352-3	2014	The purpose of this study was to develop a new lipid formulation based on nanocochleates combining two active drugs: Amphotericin B (AmB) and Miltefosine (HePC).	miltefosine	142-153	hepcidin antimicrobial peptide	Homo sapiens	155-159
25128666-6	2014	The most promising compounds 14 and 18 were about two and five fold more active than miltefosine against DU-145 and MCF-7 cell lines respectively and significantly down regulated phospho-Akt.	miltefosine	85-96	AKT serine/threonine kinase 1	Homo sapiens	187-190
24643019-9	2014	Interactions between these two compounds and miltefosine were classified as synergistic, with the most effective association being between AB13 and miltefosine, where decreases of IC50 values to 6 microM were observed, similar to the miltefosine activity alone.	miltefosine	148-159	NBPF member 1	Homo sapiens	139-143
24731805-0	2014	Functional disruption of yeast metacaspase, Mca1, leads to miltefosine resistance and inability to mediate miltefosine-induced apoptotic effects.	miltefosine	59-70	Ca(2+)-dependent cysteine protease MCA1	Saccharomyces cerevisiae S288C	44-48
24731805-0	2014	Functional disruption of yeast metacaspase, Mca1, leads to miltefosine resistance and inability to mediate miltefosine-induced apoptotic effects.	miltefosine	107-118	Ca(2+)-dependent cysteine protease MCA1	Saccharomyces cerevisiae S288C	44-48
24732039-6	2014	Animals that received liposomal CpG-ODN-2006 (lipo-CpG-ODN-2006) and sub-curative miltefosine (5 mg/kg) showed the best inhibition of parasite multiplication (~97%) which was associated with a biased Th1 immune response in.	miltefosine	82-93	negative elongation factor complex member C/D, Th1l	Mus musculus	200-203
24732039-9	2014	Collectively, our results suggest that combination of lipo-CpG-ODN-2006 and sub-curative miltefosine generates protective T-cell response in an animal model of visceral leishmaniasis which is characterized by strong Th1 biased immune response thereby underlining our hypothesis that combination therapy, at short dose regimen can be used as a novel way of treating visceral leishmaniasis.	miltefosine	89-100	negative elongation factor complex member C/D, Th1l	Mus musculus	216-219
24643019-14	2014	This study has identified the betulin derivative BT06 and the betulinic acid derivative AB13 as promising molecules in the development of new alternative therapies for leishmaniasis, including those involving combined-therapy with miltefosine.	miltefosine	231-242	NBPF member 1	Homo sapiens	88-92
24643019-9	2014	Interactions between these two compounds and miltefosine were classified as synergistic, with the most effective association being between AB13 and miltefosine, where decreases of IC50 values to 6 microM were observed, similar to the miltefosine activity alone.	miltefosine	148-159	NBPF member 1	Homo sapiens	139-143
24670148-7	2014	KEY RESULTS: Computational and biophysical studies revealed that paromomycin/miltefosine interact with TLR9.	miltefosine	77-88	toll like receptor 9	Homo sapiens	103-107
24383815-1	2014	The mechanism of binding of two promising anticancer agents (the cytotoxic alkylphospholipids perifosine and miltefosine) to the Akt PH domain is investigated by high-resolution field-cycling (31)P nuclear magnetic resonance (NMR) spectroscopy using a spin-labeled recombinant PH domain.	miltefosine	109-120	AKT serine/threonine kinase 1	Homo sapiens	129-132
24225136-7	2014	Miltefosine and erufosine induced dephosphorylation of Akt in My-La CD8+ cells and phosphorylation of JNK in Hut-78 and My-La CD8+ cells.	miltefosine	0-11	mitogen-activated protein kinase 8	Homo sapiens	102-105
27485199-2	2014	A variety of APC analogs has been synthesized and tested showing less hemolytic effect than the class prototype, Miltefosine (HePC).	miltefosine	113-124	hepcidin antimicrobial peptide	Homo sapiens	126-130
24076076-0	2013	Functional characterization of the hexose transporter Hxt13p: an efflux pump that mediates resistance to miltefosine in yeast.	miltefosine	105-116	hexose transporter HXT13	Saccharomyces cerevisiae S288C	54-60
23507869-7	2013	Miltefosine (50 muM), a licensed drug that blocks Akt phosphorylation, inhibited HSV-induced calcium release, viral entry, and plaque formation following infection with acyclovir-sensitive and resistant clinical isolates.	miltefosine	0-11	latexin	Homo sapiens	16-19
24225136-7	2014	Miltefosine and erufosine induced dephosphorylation of Akt in My-La CD8+ cells and phosphorylation of JNK in Hut-78 and My-La CD8+ cells.	miltefosine	0-11	AKT serine/threonine kinase 1	Homo sapiens	55-58
23729024-0	2013	Effectiveness of miltefosine treatment in targeting anti-leishmanial HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis patients.	miltefosine	17-28	heme oxygenase 1	Homo sapiens	69-73
23729024-0	2013	Effectiveness of miltefosine treatment in targeting anti-leishmanial HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis patients.	miltefosine	17-28	NFE2 like bZIP transcription factor 2	Homo sapiens	74-79
23729024-3	2013	We aimed to investigate the role of miltefosine in regulating HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis (VL) patients in vivo and in vitro.	miltefosine	36-47	heme oxygenase 1	Homo sapiens	62-66
23729024-3	2013	We aimed to investigate the role of miltefosine in regulating HO-1/Nrf-2-mediated oxidative responses in visceral leishmaniasis (VL) patients in vivo and in vitro.	miltefosine	36-47	NFE2 like bZIP transcription factor 2	Homo sapiens	67-72
23729024-5	2013	RT-PCR of HO-1, Nrf-2 translocation analysis and HO-1 ELISA were used to investigate the HO-1/Nrf-2-mediated modulation of oxidative responses by miltefosine in vivo.	miltefosine	146-157	NFE2 like bZIP transcription factor 2	Homo sapiens	94-99
23729024-7	2013	The in vitro HO-1/Nrf-2-dependent anti-leishmanial effect of miltefosine was assessed by the use of specific inhibitors/inducers and subsequent microscopic measurement of parasite killing and Th1/Th2 cytokine regulation by ELISA.	miltefosine	61-72	heme oxygenase 1	Homo sapiens	13-17
23729024-7	2013	The in vitro HO-1/Nrf-2-dependent anti-leishmanial effect of miltefosine was assessed by the use of specific inhibitors/inducers and subsequent microscopic measurement of parasite killing and Th1/Th2 cytokine regulation by ELISA.	miltefosine	61-72	NFE2 like bZIP transcription factor 2	Homo sapiens	18-23
23729024-7	2013	The in vitro HO-1/Nrf-2-dependent anti-leishmanial effect of miltefosine was assessed by the use of specific inhibitors/inducers and subsequent microscopic measurement of parasite killing and Th1/Th2 cytokine regulation by ELISA.	miltefosine	61-72	negative elongation factor complex member C/D	Homo sapiens	192-195
23729024-8	2013	RESULTS: Increased levels of transcript and serum HO-1, Nrf-2 nuclear translocation, serum bilirubin, GPx and SOD activity in untreated VL patients were reversed after miltefosine chemotherapy.	miltefosine	168-179	heme oxygenase 1	Homo sapiens	50-54
23729024-8	2013	RESULTS: Increased levels of transcript and serum HO-1, Nrf-2 nuclear translocation, serum bilirubin, GPx and SOD activity in untreated VL patients were reversed after miltefosine chemotherapy.	miltefosine	168-179	NFE2 like bZIP transcription factor 2	Homo sapiens	56-61
23729024-9	2013	The effectiveness of miltefosine for positive induction of ROS via NADPH correlated with a decrease in HO-1/ERK/Nrf-2-dependent parasite load.	miltefosine	21-32	heme oxygenase 1	Homo sapiens	103-107
23729024-9	2013	The effectiveness of miltefosine for positive induction of ROS via NADPH correlated with a decrease in HO-1/ERK/Nrf-2-dependent parasite load.	miltefosine	21-32	mitogen-activated protein kinase 1	Homo sapiens	108-111
23729024-9	2013	The effectiveness of miltefosine for positive induction of ROS via NADPH correlated with a decrease in HO-1/ERK/Nrf-2-dependent parasite load.	miltefosine	21-32	NFE2 like bZIP transcription factor 2	Homo sapiens	112-117
23729024-10	2013	Furthermore, HO-1 blockade by miltefosine led to suppression of interleukin-10 and transforming growth factor-beta, but enhanced interleukin-12 and tumour necrosis factor-alpha production, in VL patients.	miltefosine	30-41	heme oxygenase 1	Homo sapiens	13-17
23729024-10	2013	Furthermore, HO-1 blockade by miltefosine led to suppression of interleukin-10 and transforming growth factor-beta, but enhanced interleukin-12 and tumour necrosis factor-alpha production, in VL patients.	miltefosine	30-41	interleukin 10	Homo sapiens	64-114
23811261-7	2013	RESULTS: A 48 h exposure to miltefosine (>= 4.9 muM) was followed by significant decrease of forward scatter and significant increase of annexin-V-binding.	miltefosine	28-39	annexin A5	Homo sapiens	140-149
23811261-9	2013	The annexin-V-binding following miltefosine treatment was significantly blunted in the nominal absence of extracellular Ca(2+).	miltefosine	32-43	annexin A5	Homo sapiens	4-13
23811637-6	2013	We use the CD45RB T-cell transfer colitis model to investigate the effect of miltefosine treatment on intestinal inflammation.	miltefosine	77-88	protein tyrosine phosphatase, receptor type, C	Mus musculus	11-15
22935677-1	2013	Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study.	miltefosine	0-23	ATP binding cassette subfamily B member 1	Homo sapiens	246-268
22935677-1	2013	Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study.	miltefosine	0-23	ATP binding cassette subfamily B member 1	Homo sapiens	270-274
22935677-1	2013	Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study.	miltefosine	0-23	ATP binding cassette subfamily B member 1	Homo sapiens	289-303
22935677-1	2013	Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study.	miltefosine	0-23	ATP binding cassette subfamily B member 1	Homo sapiens	305-309
23507869-7	2013	Miltefosine (50 muM), a licensed drug that blocks Akt phosphorylation, inhibited HSV-induced calcium release, viral entry, and plaque formation following infection with acyclovir-sensitive and resistant clinical isolates.	miltefosine	0-11	AKT serine/threonine kinase 1	Homo sapiens	50-53
22361489-0	2012	Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: role of TLR4 and TLR9.	miltefosine	0-11	toll like receptor 4	Homo sapiens	103-107
23434716-2	2013	The development of new lipid formulation (nanocochleates), containing two active drugs: amphotericin B (AmB) and miltefosine (hexadecylphosphocholine, HePC), could increase effectiveness, decrease toxicity and reduce the risk of appearance of resistance.	miltefosine	113-124	hepcidin antimicrobial peptide	Homo sapiens	151-155
23415083-4	2013	Among the synthesized compounds, 5a, 5b and 6c exhibited potent inhibitory Akt phosphorylation effects with IC50 value of 3.1, 2.0 and 3.0 muM, respectively, and their potencies were better than those of three reference compounds miltefosine, perifosine and edelfosine.	miltefosine	230-241	AKT serine/threonine kinase 1	Homo sapiens	75-78
23335509-5	2013	Additional ATLs, including miltefosine and perifosine, also displaced Pma1p from rafts to the vacuole, suggesting that this process is a major hallmark of ATL cytotoxicity in yeast.	miltefosine	27-38	H(+)-exporting P2-type ATPase PMA1	Saccharomyces cerevisiae S288C	70-75
22761329-0	2012	Combination of paromomycin and miltefosine promotes TLR4-dependent induction of antileishmanial immune response in vitro.	miltefosine	31-42	toll like receptor 4	Homo sapiens	52-56
22761329-7	2012	RESULTS: Computational studies reveal that paromomycin and miltefosine interact with TLR4.	miltefosine	59-70	toll like receptor 4	Homo sapiens	85-89
22761329-11	2012	CONCLUSIONS: The in vitro activity of paromomycin and miltefosine against host cells is TLR4 dependent.	miltefosine	54-65	toll like receptor 4	Homo sapiens	88-92
22361489-0	2012	Miltefosine triggers a strong proinflammatory cytokine response during visceral leishmaniasis: role of TLR4 and TLR9.	miltefosine	0-11	toll like receptor 9	Homo sapiens	112-116
22361489-5	2012	This Miltefosine induced proinflammatory cytokine response in infected THP1 cells was also accompanied by simultaneous 10- and 12-fold increase in TLR4 mRNA and TLR9 mRNA.	miltefosine	5-16	toll like receptor 4	Homo sapiens	147-151
22361489-5	2012	This Miltefosine induced proinflammatory cytokine response in infected THP1 cells was also accompanied by simultaneous 10- and 12-fold increase in TLR4 mRNA and TLR9 mRNA.	miltefosine	5-16	toll like receptor 9	Homo sapiens	161-165
22361489-7	2012	Thereby, suggesting a probable dependence of Miltefosine on TLR4 and TLR9 in triggering a proinflammatory response.	miltefosine	45-56	toll like receptor 4	Homo sapiens	60-64
22361489-7	2012	Thereby, suggesting a probable dependence of Miltefosine on TLR4 and TLR9 in triggering a proinflammatory response.	miltefosine	45-56	toll like receptor 9	Homo sapiens	69-73
21933878-4	2011	RESULTS: Miltefosine on circulating monocytes upregulated expression of CD16 and CD86 and reduced that of CD14.	miltefosine	9-20	Fc gamma receptor IIIa	Homo sapiens	72-76
22870283-0	2012	Leishmania promastigotes lack phosphatidylserine but bind annexin V upon permeabilization or miltefosine treatment.	miltefosine	93-104	annexin A5	Homo sapiens	58-67
22870283-4	2012	Here we show that Leishmania promastigotes can be stained by fluorescence-labeled annexin V upon permeabilization or miltefosine treatment.	miltefosine	117-128	annexin A5	Homo sapiens	82-91
22138309-3	2012	Of the compounds synthesized, compound 6d most potently inhibited Akt phosphorylation with an IC(50) value of 3.6 muM, its potency was greater than the reference compounds miltefosine, perifosine, and erufosine.	miltefosine	172-183	AKT serine/threonine kinase 1	Homo sapiens	66-69
21933878-4	2011	RESULTS: Miltefosine on circulating monocytes upregulated expression of CD16 and CD86 and reduced that of CD14.	miltefosine	9-20	CD86 molecule	Homo sapiens	81-85
21933878-4	2011	RESULTS: Miltefosine on circulating monocytes upregulated expression of CD16 and CD86 and reduced that of CD14.	miltefosine	9-20	CD14 molecule	Homo sapiens	106-110
22121288-5	2011	Keeping in mind the higher rate of side effects to pentavalent antimony, we treated this patient with oral miltefosine 50 mg bid and the lesions showed complete resolution over 4 months of therapy.	miltefosine	107-118	BH3 interacting domain death agonist	Homo sapiens	125-128
21610197-0	2011	Miltefosine induces apoptosis-like cell death in yeast via Cox9p in cytochrome c oxidase.	miltefosine	0-11	cytochrome c oxidase subunit VIIa	Saccharomyces cerevisiae S288C	59-64
21610197-4	2011	COX9, which encodes subunit VIIa of the cytochrome c oxidase (COX) complex in the electron transport chain of the mitochondrial membrane, was identified as a potential target of miltefosine from a genomic library screen of the model yeast Saccharomyces cerevisiae.	miltefosine	178-189	cytochrome c oxidase subunit VIIa	Saccharomyces cerevisiae S288C	0-4
21610197-5	2011	When overexpressed in S. cerevisiae, COX9, but not COX7 or COX8, led to a miltefosine-resistant phenotype.	miltefosine	74-85	cytochrome c oxidase subunit VIIa	Saccharomyces cerevisiae S288C	37-41
21610197-6	2011	The effect of miltefosine on COX activity was assessed in cells expressing different levels of COX9.	miltefosine	14-25	cytochrome c oxidase subunit VIIa	Saccharomyces cerevisiae S288C	95-99
21610197-7	2011	Miltefosine inhibited COX activity in a dose-dependent manner in Cox9p-positive cells.	miltefosine	0-11	cytochrome c oxidase subunit VIIa	Saccharomyces cerevisiae S288C	65-70
20338039-5	2010	Likewise, treatment with miltefosine produces an interference with the biosynthesis of phosphatidylcholine via both CDP-choline and phosphatidylethanolamine methylation.	miltefosine	25-36	cut like homeobox 1	Homo sapiens	116-119
20495208-9	2010	CONCLUSIONS: Promising antileishmanial efficacy was observed in animals treated with liposomal CpG ODN and miltefosine, strongly supported by enhancement of Th1 cytokines as well as NO, ROS and H(2)O(2) levels.	miltefosine	107-118	negative elongation factor complex member C/D, Th1l	Mus musculus	157-160
21569375-5	2011	RESULTS: Miltefosine proved to have in vitro ovicidal, schistolarvicidal and lethal activity on adult worms of both Schistosoma species and has considerable molluscicidal activity on their snail hosts.	miltefosine	9-20	snail family transcriptional repressor 1	Homo sapiens	189-194
20922428-5	2011	The activity was compared with that of standard drugs, edelfosine (IC50 = 0.82 +- 0.13 muM) and miltefosine (IC50 = 2.84 +- 0.10 muM).	miltefosine	96-107	latexin	Homo sapiens	129-132
20337610-11	2010	Moreover, increased FoxP3(+) cells were present in the skin after miltefosine treatment (before 5.4% [1.9-9.8], after 6.2% [3.5-9.5]).	miltefosine	66-77	forkhead box P3	Homo sapiens	20-25
19041866-1	2008	This study describes the molecular signaling involved in the different cell death modes of triple-negative breast cancer cells induced by hexadecylphosphocholine (HePC/miltefosine), a clinically relevant anticancer alkylphosphocholine.	miltefosine	138-161	hepcidin antimicrobial peptide	Homo sapiens	163-167
19917276-10	2010	Miltefosine significantly attenuated the allergic sensitization in the model of ovalbumin induced delayed-type hypersensitivity in mice.	miltefosine	0-11	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	80-89
19917276-12	2010	The data indicate that miltefosine modulates T-cell function in models for Th1 and Th2 related activity.	miltefosine	23-34	negative elongation factor complex member C/D	Homo sapiens	75-78
19549672-4	2009	In a previous study we discovered that miltefosine (hexadecylphosphocholine) is highly active against Acanthamoeba spp.	miltefosine	39-50	histocompatibility minor 13	Homo sapiens	115-118
19549672-4	2009	In a previous study we discovered that miltefosine (hexadecylphosphocholine) is highly active against Acanthamoeba spp.	miltefosine	52-75	histocompatibility minor 13	Homo sapiens	115-118
19442087-1	2009	Miltefosine (hexadecylphosphocholine, HePC) is an alkyl phospholipid which was first developed as an anticancer agent for local treatment of skin metastases.	miltefosine	0-11	hepcidin antimicrobial peptide	Homo sapiens	38-42
18710416-4	2008	Treatment with miltefosine resulted in increase in Ras, extracellular signal-regulated kinase (ERK) and p38MAPK activity.	miltefosine	15-26	mitogen-activated protein kinase 1	Homo sapiens	56-93
18710416-0	2008	Involvement of miltefosine-mediated ERK activation in glioma cell apoptosis through Fas regulation.	miltefosine	15-26	mitogen-activated protein kinase 1	Homo sapiens	36-39
18710416-3	2008	In this study, we demonstrate that miltefosine-induced apoptosis is accompanied by elevated Fas, Fas-associated death domain (FADD) expression, caspase-8 activity and the increased distribution of Fas and FADD towards lipid raft microdomain to form death inducing signaling complex.	miltefosine	35-46	caspase 8	Homo sapiens	144-153
18639311-3	2008	A significant increase in IFNgamma and CD40 levels seen after miltefosine therapy could enhance parasite clearance.	miltefosine	62-73	interferon gamma	Homo sapiens	26-34
18639311-3	2008	A significant increase in IFNgamma and CD40 levels seen after miltefosine therapy could enhance parasite clearance.	miltefosine	62-73	CD40 molecule	Homo sapiens	39-43
18710416-4	2008	Treatment with miltefosine resulted in increase in Ras, extracellular signal-regulated kinase (ERK) and p38MAPK activity.	miltefosine	15-26	mitogen-activated protein kinase 1	Homo sapiens	95-98
18710416-6	2008	Although inhibition of both ERK and p38MAPK decreased the pro-apoptotic effects of miltefosine, it was the inhibition of ERK and not p38MAPK activation that decreased Fas and FADD expression.	miltefosine	83-94	mitogen-activated protein kinase 1	Homo sapiens	28-31
18710416-8	2008	Taken together, our findings suggest the involvement of ERK activation in miltefosine-induced glioma cell apoptosis.	miltefosine	74-85	mitogen-activated protein kinase 1	Homo sapiens	56-59
17700717-3	2007	EXPERIMENTAL APPROACH: A variety of lipids, including lysophosphatidylcholine, sphingosylphosphorylcholine and hexadecylphosphorylcholine were studied for their effect on P2X(7) receptor-stimulated ethidium bromide accumulation in cells expressing human recombinant P2X(7) receptors and on P2X(7) receptor-stimulated interleukin-1 beta (IL1 beta) release from THP-1 cells.	miltefosine	111-137	purinergic receptor P2X 7	Homo sapiens	171-186
18843901-3	2008	Once treatment for leishmaniasis was started with miltefosine, CD4+ cell count rose above 400/microL.	miltefosine	50-61	CD4 molecule	Homo sapiens	63-66
18312412-7	2008	The activity of 3-hydroxy-3-methylglutaryl-CoA reductase (EC 1.1.1.34) and low-density lipoprotein receptor, as well as the corresponding mRNA expression, increased after 24 h of treatment with hexadecylphosphocholine.	miltefosine	194-217	3-hydroxy-3-methylglutaryl-CoA reductase	Homo sapiens	16-56
18312412-7	2008	The activity of 3-hydroxy-3-methylglutaryl-CoA reductase (EC 1.1.1.34) and low-density lipoprotein receptor, as well as the corresponding mRNA expression, increased after 24 h of treatment with hexadecylphosphocholine.	miltefosine	194-217	low density lipoprotein receptor	Homo sapiens	75-107
18237430-2	2008	RESULTS: Here, we demonstrate that PI3K/Akt inhibitors, including clinically available Miltefosine, dramatically reduced HIV-1 production from long-living virus-infected macrophages.	miltefosine	87-98	AKT serine/threonine kinase 1	Homo sapiens	40-43
17161839-4	2007	However, there are discrepancies regarding the involvement of P-glycoprotein (Pgp) and sensitivity of miltefosine in multiple drug-resistant (MDR) cell lines that overexpress Pgp in Leishmania.	miltefosine	102-113	p-glycoprotein	Leishmania donovani	175-178
17890828-4	2007	One patient of miltefosine group treated outside only on the basis of rK-39 positivity did not show LD bodies in splenic aspirates and improved without any antikala- azar drug.	miltefosine	15-26	keratin 39	Rattus norvegicus	70-75
16966395-1	2006	The aim of this study was to evaluate the potential of a combination of two antileishmanial drugs, miltefosine (HePC) and amphotericin B (AMB), when administered by the oral route.	miltefosine	99-110	hepcidin antimicrobial peptide	Homo sapiens	112-116
17215888-6	2006	We show that lipid-based anti-cancer drugs, such as miltefosine, and signaling molecules, such as platelet-activating factors, bind saturably to Pgp with Kd values in the low micromolar range, and modulate its ATPase activity.	miltefosine	52-63	phosphoglycolate phosphatase	Homo sapiens	145-148
17393228-1	2007	Miltefosine (hexadecylphosphocholine, HePC) is the first effective oral agent for the treatment of visceral leishmaniasis.	miltefosine	0-11	hepcidin antimicrobial peptide	Homo sapiens	38-42
17252190-1	2007	PURPOSE: This study aimed to characterize the transepithelial transport of miltefosine (HePC), the first orally effective drug against visceral leishmaniasis, across the intestinal barrier to further understand its oral absorption mechanism.	miltefosine	75-86	hepcidin antimicrobial peptide	Homo sapiens	88-92
16752184-1	2006	AIMS/HYPOTHESIS: Miltefosine, the first oral anti-leishmanial drug, is reported to inhibit phosphatidylinositol 3-kinase (PI3K)/Akt activity in carcinoma cell lines.	miltefosine	17-28	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta	Rattus norvegicus	91-120
16940108-3	2006	We have previously shown the involvement of LtrMDR1, a P-glycoprotein-like transporter belonging to the ATP-binding cassette superfamily, in miltefosine resistance in Leishmania.	miltefosine	141-152	ATP binding cassette subfamily B member 1	Homo sapiens	55-69
16940108-9	2006	The results show that this combinatorial strategy efficiently overcomes P-glycoprotein-mediated parasite miltefosine resistance by increasing intracellular miltefosine accumulation without any side effect in the parental, sensitive, Leishmania line and in different mammalian cell lines.	miltefosine	105-116	ATP binding cassette subfamily B member 1	Homo sapiens	72-86
16940108-9	2006	The results show that this combinatorial strategy efficiently overcomes P-glycoprotein-mediated parasite miltefosine resistance by increasing intracellular miltefosine accumulation without any side effect in the parental, sensitive, Leishmania line and in different mammalian cell lines.	miltefosine	156-167	ATP binding cassette subfamily B member 1	Homo sapiens	72-86
16752184-1	2006	AIMS/HYPOTHESIS: Miltefosine, the first oral anti-leishmanial drug, is reported to inhibit phosphatidylinositol 3-kinase (PI3K)/Akt activity in carcinoma cell lines.	miltefosine	17-28	AKT serine/threonine kinase 1	Rattus norvegicus	128-131
16752184-4	2006	MATERIALS AND METHODS: L6E9 myotubes were treated with miltefosine and its effect was observed on insulin-signalling proteins such as Akt, PI3K, insulin receptor-beta, IRS-1, c-Jun N-terminal kinase, p38 and glycogen synthase kinase beta, as well as on glucose uptake.	miltefosine	55-66	AKT serine/threonine kinase 1	Rattus norvegicus	134-137
16752184-4	2006	MATERIALS AND METHODS: L6E9 myotubes were treated with miltefosine and its effect was observed on insulin-signalling proteins such as Akt, PI3K, insulin receptor-beta, IRS-1, c-Jun N-terminal kinase, p38 and glycogen synthase kinase beta, as well as on glucose uptake.	miltefosine	55-66	insulin receptor substrate 1	Rattus norvegicus	168-173
16752184-4	2006	MATERIALS AND METHODS: L6E9 myotubes were treated with miltefosine and its effect was observed on insulin-signalling proteins such as Akt, PI3K, insulin receptor-beta, IRS-1, c-Jun N-terminal kinase, p38 and glycogen synthase kinase beta, as well as on glucose uptake.	miltefosine	55-66	mitogen activated protein kinase 14	Rattus norvegicus	200-203
16510923-6	2006	Miltefosine is able to change immunological reactions to enhance the immune response of interleukin-2-stimulating mononuclear cells, resulting in interferon gamma gene expression and interferon gamma secretion.	miltefosine	0-11	interleukin 2	Homo sapiens	88-101
16337152-1	2006	Miltefosine (hexadecylphosphocholine, HePC) is the first effective oral agent for the treatment of visceral leishmaniasis.	miltefosine	0-11	hepcidin antimicrobial peptide	Homo sapiens	38-42
16436691-1	2006	The alkyl phosphocholine drug miltefosine is structurally similar to natural substrates of the fungal virulence determinant phospholipase B1 (PLB1), which is a potential drug target.	miltefosine	30-41	phospholipase B1	Mus musculus	124-140
16436691-1	2006	The alkyl phosphocholine drug miltefosine is structurally similar to natural substrates of the fungal virulence determinant phospholipase B1 (PLB1), which is a potential drug target.	miltefosine	30-41	phospholipase B1	Mus musculus	142-146
16436691-2	2006	We determined the MICs of miltefosine against key fungal pathogens, correlated antifungal activity with inhibition of the PLB1 activities (PLB, lysophospholipase [LPL], and lysophospholipase-transacylase [LPTA]), and investigated its efficacy in a mouse model of disseminated cryptococcosis.	miltefosine	26-37	phospholipase B1	Mus musculus	122-126
16436691-2	2006	We determined the MICs of miltefosine against key fungal pathogens, correlated antifungal activity with inhibition of the PLB1 activities (PLB, lysophospholipase [LPL], and lysophospholipase-transacylase [LPTA]), and investigated its efficacy in a mouse model of disseminated cryptococcosis.	miltefosine	26-37	phospholamban	Mus musculus	122-125
16436691-3	2006	Miltefosine inhibited secreted cryptococcal LPTA activity by 35% at the subhemolytic concentration of 25 microM (10.2 microg/ml) and was inactive against mammalian pancreatic phospholipase A2 (PLA2).	miltefosine	0-11	phospholipase A2 group IB	Homo sapiens	193-197
16466701-4	2006	Interestingly, we demonstrate for the first time that HePC strongly inhibits the esterification of free cholesterol (FC) by acting at the level of acyl CoA:cholesterol acyltransferase (ACAT) (EC 2.3.1.26) activity.	miltefosine	54-58	sterol O-acyltransferase 1	Homo sapiens	147-183
16466701-4	2006	Interestingly, we demonstrate for the first time that HePC strongly inhibits the esterification of free cholesterol (FC) by acting at the level of acyl CoA:cholesterol acyltransferase (ACAT) (EC 2.3.1.26) activity.	miltefosine	54-58	sterol O-acyltransferase 1	Homo sapiens	185-189
16510923-6	2006	Miltefosine is able to change immunological reactions to enhance the immune response of interleukin-2-stimulating mononuclear cells, resulting in interferon gamma gene expression and interferon gamma secretion.	miltefosine	0-11	interferon gamma	Homo sapiens	146-162
16510923-6	2006	Miltefosine is able to change immunological reactions to enhance the immune response of interleukin-2-stimulating mononuclear cells, resulting in interferon gamma gene expression and interferon gamma secretion.	miltefosine	0-11	interferon gamma	Homo sapiens	183-199
14592540-0	2004	Hexadecylphosphocholine inhibits phosphatidylcholine synthesis via both the methylation of phosphatidylethanolamine and CDP-choline pathways in HepG2 cells.	miltefosine	0-23	cut like homeobox 1	Homo sapiens	120-123
15773125-6	2004	However, at pH 10 the highest stability occurs for mixtures containing a smaller proportion of miltefosine (XM = 0.5), which means that on alkaline subphases the ability to condense the miltefosine monolayer by cholesterol is less efficient as it requires a higher proportion of cholesterol (1:1 as compared to 1:2 at pH 2 and 6) to attain the maximum stability of the mixed film.	miltefosine	95-106	polyhomeotic homolog 2	Homo sapiens	318-328
15773125-6	2004	However, at pH 10 the highest stability occurs for mixtures containing a smaller proportion of miltefosine (XM = 0.5), which means that on alkaline subphases the ability to condense the miltefosine monolayer by cholesterol is less efficient as it requires a higher proportion of cholesterol (1:1 as compared to 1:2 at pH 2 and 6) to attain the maximum stability of the mixed film.	miltefosine	186-197	polyhomeotic homolog 2	Homo sapiens	318-328
14592540-1	2004	We reported in a recent publication that hexadecylphosphocholine (HePC), a lysophospholipid analogue, reduces cell proliferation in HepG2 cells and at the same time inhibits the biosynthesis of phosphatidylcholine (PC) via CDP-choline by acting upon CTP:phosphocholine cytidylyltransferase (CT).	miltefosine	41-64	cut like homeobox 1	Homo sapiens	223-226
14592540-5	2004	We also analyzed the water-soluble intermediates and final product of the CDP-ethanolamine pathway and found that HePC caused an increase in the incorporation of [1,2-14C]ethanolamine into CDP-ethanolamine and phosphatidylethanolamine (PE) and a decrease in ethanolamine phosphate, which might be interpreted in terms of a stimulation of CTP:phosphoethanolamine cytidylyltransferase activity.	miltefosine	114-118	cut like homeobox 1	Homo sapiens	74-77
14592540-5	2004	We also analyzed the water-soluble intermediates and final product of the CDP-ethanolamine pathway and found that HePC caused an increase in the incorporation of [1,2-14C]ethanolamine into CDP-ethanolamine and phosphatidylethanolamine (PE) and a decrease in ethanolamine phosphate, which might be interpreted in terms of a stimulation of CTP:phosphoethanolamine cytidylyltransferase activity.	miltefosine	114-118	cut like homeobox 1	Homo sapiens	189-192
11551522-4	2001	Wild-type p53 containing WMN Burkitt"s lymphoma cells and wild type p53-deficient CA46 exhibited similar sensitivities to miltefosine.	miltefosine	122-133	tumor protein p53	Homo sapiens	10-13
12230578-7	2002	Treatment with HePC altered neither the activity of choline kinase (CK) nor that of diacylglycerol cholinephosphotransferase (CPT), but it did inhibit CT activity in HepG2 cells.	miltefosine	15-19	choline phosphotransferase 1	Homo sapiens	126-129
12842877-0	2003	Lem3p is essential for the uptake and potency of alkylphosphocholine drugs, edelfosine and miltefosine.	miltefosine	91-102	Lem3p	Saccharomyces cerevisiae S288C	0-5
11888912-11	2002	Similar results were obtained with other ALK congeners (miltefosine and edelfosine).	miltefosine	56-67	ALK receptor tyrosine kinase	Homo sapiens	41-44
11551522-5	2001	The low percentage of apoptosis induced in MCF7 cells lacking caspase 3 indicated that caspase 3 seems to play an essential role in miltefosine-induced apoptosis.	miltefosine	132-143	caspase 3	Homo sapiens	87-96
10463770-0	1999	Bcl-2 plays a key role instead of mdr1 in the resistance to hexadecylphosphocholine in human epidermoid tumor cell line KB.	miltefosine	60-83	BCL2 apoptosis regulator	Homo sapiens	0-5
11314048-0	2001	Modulation of phospholipase D by hexadecylphosphorylcholine: a putative novel mechanism for its antitumoral activity.	miltefosine	33-59	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	14-29
10669380-2	2000	In vitro, miltefosine stimulates T cells and macrophages to respond to and secrete activating cytokines, including interferon (IFN)-gamma, and enhances macrophage production of microbicidal reactive nitrogen and oxygen intermediates (RNIs and ROIs, respectively).	miltefosine	10-21	interferon gamma	Mus musculus	115-137
10628349-1	1999	The alkylphosphocholine Miltefosine (hexadecylphosphocholine, HePC) induces apoptosis in human epithelial KB cells, whereas no such effect can be observed in a resistant clone (KBres).	miltefosine	24-35	hepcidin antimicrobial peptide	Homo sapiens	62-66
11355955-0	2001	MDR1 causes resistance to the antitumour drug miltefosine.	miltefosine	46-57	ATP binding cassette subfamily B member 1	Homo sapiens	0-4
11355955-3	2001	We investigated the sensitivity of MDR1 -expressing cells to treatment with miltefosine.	miltefosine	76-87	ATP binding cassette subfamily B member 1	Homo sapiens	35-39
11355955-4	2001	We show that cells overexpressing MDR1 (NCI/ADR-RES, KB-8-5, KB-C1, CCRF/VCR1000, CCRF/ADR5000) were less sensitive to miltefosine treatment when compared to the sensitive parental cell lines.	miltefosine	119-130	ATP binding cassette subfamily B member 1	Homo sapiens	34-38
11355955-5	2001	HeLa cells transfected with MDR1 exhibited resistance to the compound, indicating that expression of this gene is sufficient to reduce the sensitivity to miltefosine.	miltefosine	154-165	ATP binding cassette subfamily B member 1	Homo sapiens	28-32
11355955-6	2001	The resistance of MDR1-expressing cells to miltefosine was less pronounced than that to adriamycin or vinblastine.	miltefosine	43-54	ATP binding cassette subfamily B member 1	Homo sapiens	18-22
11355955-8	2001	As shown by a fluorescence quenching assay using MIANS-labelled P-glycoprotein (PGP), miltefosine bound to PGP with a K(d)of approximately 7 microM and inhibited PGP-ATPase activity with an IC(50)of approximately 35 microM.	miltefosine	86-97	ATP binding cassette subfamily B member 1	Homo sapiens	64-78
11355955-8	2001	As shown by a fluorescence quenching assay using MIANS-labelled P-glycoprotein (PGP), miltefosine bound to PGP with a K(d)of approximately 7 microM and inhibited PGP-ATPase activity with an IC(50)of approximately 35 microM.	miltefosine	86-97	ATP binding cassette subfamily B member 1	Homo sapiens	80-83
11355955-8	2001	As shown by a fluorescence quenching assay using MIANS-labelled P-glycoprotein (PGP), miltefosine bound to PGP with a K(d)of approximately 7 microM and inhibited PGP-ATPase activity with an IC(50)of approximately 35 microM.	miltefosine	86-97	ATP binding cassette subfamily B member 1	Homo sapiens	107-110
11355955-8	2001	As shown by a fluorescence quenching assay using MIANS-labelled P-glycoprotein (PGP), miltefosine bound to PGP with a K(d)of approximately 7 microM and inhibited PGP-ATPase activity with an IC(50)of approximately 35 microM.	miltefosine	86-97	ATP binding cassette subfamily B member 1	Homo sapiens	107-110
11355955-12	2001	These data indicate that expression of MDR1 may reduce the response to miltefosine in patients and that this compound interacts with PGP in a manner different from a number of other substrates.	miltefosine	71-82	ATP binding cassette subfamily B member 1	Homo sapiens	39-43
11190577-10	2001	Despite these problems, PKC modulators such as miltefosine, bryostatin, safingol, CGP41251 and UCN-01 are used in the clinic or are in clinical evaluation.	miltefosine	47-58	protein kinase C alpha	Homo sapiens	24-27
9264326-0	1997	Differential regulation of phospholipase A2 in human leukemia cells by the etherphospholipid analogue hexadecylphosphocholine.	miltefosine	102-125	phospholipase A2 group IB	Homo sapiens	27-43
9302654-1	1997	Hexadecylphosphocholine (HePC) reduced the growth of the human mammary tumor, MX-1, in the athymic nude mouse similar to the fish oil, MaxEPA.	miltefosine	0-23	MX dynamin like GTPase 1	Homo sapiens	78-82
9302654-1	1997	Hexadecylphosphocholine (HePC) reduced the growth of the human mammary tumor, MX-1, in the athymic nude mouse similar to the fish oil, MaxEPA.	miltefosine	25-29	MX dynamin like GTPase 1	Homo sapiens	78-82
7639930-1	1995	The interference of several new hexadecylphosphocholine analogues with mitogenic signal transduction was investigated in NIH3T3 fibroblasts by studying the effects of these agents on thrombin-induced inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) formation and the subsequent Ca2+ release, on protein kinase C (PKC) in cell-free extracts, on the PKC-mediated activation of the Na+/H+ antiporter and on c-fos induction.	miltefosine	32-55	coagulation factor II	Mus musculus	183-191
9191309-0	1997	IL-1 gene expression in human mammary tumour xenografts after treatment with hexadecylphosphocholine.	miltefosine	77-100	interleukin 1 alpha	Homo sapiens	0-4
9128765-0	1997	The phospholipid analogue hexadecylphosphocholine (HePC) inhibits proliferation of keloid fibroblasts in vitro and modulates their fibronectin and integrin synthesis.	miltefosine	26-49	fibronectin 1	Homo sapiens	131-142
9128765-0	1997	The phospholipid analogue hexadecylphosphocholine (HePC) inhibits proliferation of keloid fibroblasts in vitro and modulates their fibronectin and integrin synthesis.	miltefosine	51-55	fibronectin 1	Homo sapiens	131-142
9414418-6	1996	HePC inhibited fMLP induced phosphatidylinositol-specific PLC activation in HL60 cells and TNF-alpha induced activation of phosphatidylcholine-specific PLC in U937 cells.	miltefosine	0-4	formyl peptide receptor 1	Homo sapiens	15-19
8620456-0	1996	The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D.	miltefosine	35-58	glycosylphosphatidylinositol specific phospholipase D1	Homo sapiens	79-94
7882461-1	1995	The cytotoxicity of the antineoplastic drug hexadecylphosphocholine (HePC) was determined in a human monocytic tumor cell line, THP1, and in primary cultures of rat mesangial cells.	miltefosine	44-67	GLI family zinc finger 2	Homo sapiens	128-132
7882461-1	1995	The cytotoxicity of the antineoplastic drug hexadecylphosphocholine (HePC) was determined in a human monocytic tumor cell line, THP1, and in primary cultures of rat mesangial cells.	miltefosine	69-73	GLI family zinc finger 2	Homo sapiens	128-132
8055932-3	1994	In the presence of n-hexadecylphosphocholine, the losses of activity in micellar diheptanoyl-lecithin were 80, 35, and 10% in bovine phospholipase A2, pig iso-phospholipase A2, and pig phospholipase A2, respectively.	miltefosine	19-44	LOC104974671	Bos taurus	133-149
7797600-5	1995	Closer investigation of the time sequence of this synergistic effect demonstrated that cells, that had first been treated with hexadecylphosphocholine (HPC)-MLV and 4 h later with lipopolysaccharide secreted significantly more TNF into the supernatants than in the experiment where both substances were added simultaneously.	miltefosine	127-150	tumor necrosis factor	Homo sapiens	227-230
7797600-5	1995	Closer investigation of the time sequence of this synergistic effect demonstrated that cells, that had first been treated with hexadecylphosphocholine (HPC)-MLV and 4 h later with lipopolysaccharide secreted significantly more TNF into the supernatants than in the experiment where both substances were added simultaneously.	miltefosine	152-155	tumor necrosis factor	Homo sapiens	227-230
7883777-0	1995	Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro.	miltefosine	13-36	tumor necrosis factor	Mus musculus	55-76
8055932-3	1994	In the presence of n-hexadecylphosphocholine, the losses of activity in micellar diheptanoyl-lecithin were 80, 35, and 10% in bovine phospholipase A2, pig iso-phospholipase A2, and pig phospholipase A2, respectively.	miltefosine	19-44	LOC104974671	Bos taurus	159-175
8055932-3	1994	In the presence of n-hexadecylphosphocholine, the losses of activity in micellar diheptanoyl-lecithin were 80, 35, and 10% in bovine phospholipase A2, pig iso-phospholipase A2, and pig phospholipase A2, respectively.	miltefosine	19-44	LOC104974671	Bos taurus	159-175
8045054-8	1994	Hexadecylphosphocholine, a new, well-tolerated topical agent, induced a remission rate of 50%, with 25% complete remission in CTCL patients of stage Ia to IIb.	miltefosine	0-23	TSPY like 2	Homo sapiens	126-130
1279741-0	1992	Hexadecylphosphocholine amplifies the effect of granulocyte colony-stimulating factor on differentiating hematopoietic progenitor cells.	miltefosine	0-23	colony stimulating factor 3	Homo sapiens	48-85
8435099-1	1993	The antineoplastic compound hexadecylphosphorylcholine (HPC) was shown to be a highly effective inhibitor of phospholipase C delta (PLC delta 1), with an I50 of about 30 nmol/mL (30 microM) in the presence and absence of 200 microM spermine.	miltefosine	28-54	phospholipase C delta 1	Homo sapiens	132-143
8435099-1	1993	The antineoplastic compound hexadecylphosphorylcholine (HPC) was shown to be a highly effective inhibitor of phospholipase C delta (PLC delta 1), with an I50 of about 30 nmol/mL (30 microM) in the presence and absence of 200 microM spermine.	miltefosine	56-59	phospholipase C delta 1	Homo sapiens	132-143
1555249-0	1992	Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells.	miltefosine	0-23	interferon gamma	Homo sapiens	32-48
1555249-0	1992	Hexadecylphosphocholine induces interferon-gamma secretion and expression of GM-CSF mRNA in human mononuclear cells.	miltefosine	0-23	colony stimulating factor 2	Homo sapiens	77-83
1555249-1	1992	The effects of hexadecylphosphocholine (HePC) on secretion of interferon-gamma (IFN-gamma) and steady-state levels of IFN-gamma and GM-CSF mRNA were studied in human mononuclear cells.	miltefosine	40-44	interferon gamma	Homo sapiens	62-78
8428795-5	1993	Only hexadecylphosphocholine (16:0-PC) differed in its activity, being least active in 1/C2, 1/C32 and MDA-MB-231 cells, moderately active in KB and MCF-7 cells, and most active in HT-29 cells.	miltefosine	5-28	TBL1X/Y related 1	Homo sapiens	89-98
1374341-0	1992	Hexadecylphosphocholine stimulates the colony-stimulating factor-dependent growth of hemopoietic progenitor cells.	miltefosine	0-23	colony stimulating factor 2	Homo sapiens	39-64
1374341-1	1992	The effect of the antitumorally active hexadecylphosphocholine (He-PC) on the colony-stimulating factor (CSF)-dependent growth of human hemopoietic progenitor cells was studied.	miltefosine	39-62	colony stimulating factor 2	Homo sapiens	78-103
1374341-1	1992	The effect of the antitumorally active hexadecylphosphocholine (He-PC) on the colony-stimulating factor (CSF)-dependent growth of human hemopoietic progenitor cells was studied.	miltefosine	39-62	colony stimulating factor 2	Homo sapiens	105-108
1909215-0	1991	Hexadecylphosphocholine-mediated enhancement of T-cell responses to interleukin 2.	miltefosine	0-23	interleukin 2	Homo sapiens	68-81
34841679-8	2021	Among them, miltefosine transcriptionally inhibited checkpoint kinase 1 (CHEK1), indicating that LR integrity is essential for CHEK1 expression regulation.	miltefosine	12-23	checkpoint kinase 1	Homo sapiens	52-71
1374341-2	1992	At low concentrations He-PC stimulated the CSF-dependent progenitor cell colony growth of three patients suffering from chronic myeloid leukemia (CML) and of three of six patients without hematological disorders.	miltefosine	22-27	colony stimulating factor 2	Homo sapiens	43-46
1374341-5	1992	At higher concentrations He-PC displayed suppressive effects, most pronounced in the case of G-CSF-dependent colony growth.	miltefosine	25-30	colony stimulating factor 3	Homo sapiens	93-98
34627051-9	2021	Finally, a PI3K/AKT inhibitor (Miltefosine) was used to inhibit the PI3K/AKT pathway, which reversed the inhibitory effect of PAI-1 on the apoptosis of BGCs (P < 0.05), and enhanced the promotion effect of miR-10b on the apoptosis of BGCs (P < 0.05).	miltefosine	31-42	AKT serine/threonine kinase 1	Bos taurus	16-19
34627051-9	2021	Finally, a PI3K/AKT inhibitor (Miltefosine) was used to inhibit the PI3K/AKT pathway, which reversed the inhibitory effect of PAI-1 on the apoptosis of BGCs (P < 0.05), and enhanced the promotion effect of miR-10b on the apoptosis of BGCs (P < 0.05).	miltefosine	31-42	AKT serine/threonine kinase 1	Bos taurus	73-76
34627051-9	2021	Finally, a PI3K/AKT inhibitor (Miltefosine) was used to inhibit the PI3K/AKT pathway, which reversed the inhibitory effect of PAI-1 on the apoptosis of BGCs (P < 0.05), and enhanced the promotion effect of miR-10b on the apoptosis of BGCs (P < 0.05).	miltefosine	31-42	serpin family E member 1	Bos taurus	126-131
34627051-9	2021	Finally, a PI3K/AKT inhibitor (Miltefosine) was used to inhibit the PI3K/AKT pathway, which reversed the inhibitory effect of PAI-1 on the apoptosis of BGCs (P < 0.05), and enhanced the promotion effect of miR-10b on the apoptosis of BGCs (P < 0.05).	miltefosine	31-42	microRNA 10b	Bos taurus	206-213
1965411-7	1990	The response to cis-platin, a platin derivative and hexadecyl-phosphocholine was studied on the HIV LTR and H-ras1 regulated CAT activity in RFBHIV1-1 and RF202A-1 cells.	miltefosine	52-76	HRas proto-oncogene, GTPase	Homo sapiens	108-114
34897360-5	2021	We recently showed that in situ hydrogel embedded with miltefosine (HePc, proapoptotic anti-tumor agent) and temozolomide (TMZ, DNA methylating agent) loaded targeted nanovesicles prevented tumor relapses in orthotopic GBM mouse models.	miltefosine	55-66	hepcidin antimicrobial peptide	Mus musculus	68-72
34841679-8	2021	Among them, miltefosine transcriptionally inhibited checkpoint kinase 1 (CHEK1), indicating that LR integrity is essential for CHEK1 expression regulation.	miltefosine	12-23	checkpoint kinase 1	Homo sapiens	73-78
34841679-8	2021	Among them, miltefosine transcriptionally inhibited checkpoint kinase 1 (CHEK1), indicating that LR integrity is essential for CHEK1 expression regulation.	miltefosine	12-23	checkpoint kinase 1	Homo sapiens	127-132
34841679-10	2021	However, inhibition of the LR/CHEK1 axis by miltefosine released cell cycle checkpoints, forcing CSCs to enter inappropriate mitosis with accumulated DNA damage and resulting in catastrophic cell death.	miltefosine	44-55	checkpoint kinase 1	Homo sapiens	30-35
34277476-5	2021	The experimental group (M+P) received 50 mg twice a day (BID) miltefosine and 400 mg three times a day (TID) pentoxifylline, and the control group (A+P) received 20 mg Sb+V/kg/day intravenously and 400 mg TID pentoxifylline.	miltefosine	62-73	BH3 interacting domain death agonist	Homo sapiens	57-60
34406420-5	2021	In this study, miltefosine and octenidine were identified as new HSP90 inhibitors.	miltefosine	15-26	heat shock protein 90 alpha family class A member 1	Homo sapiens	65-70
34406420-7	2021	Western blotting analysis revealed that miltefosine and octenidine significantly down-regulated the expression levels of HSP90 client proteins including p-AKT, CDK6, and ERK, and did not induce overexpression of heat shock proteins including HSP70 and HSP90 in MCF-7 cells.	miltefosine	40-51	heat shock protein 90 alpha family class A member 1	Homo sapiens	121-126
34406420-7	2021	Western blotting analysis revealed that miltefosine and octenidine significantly down-regulated the expression levels of HSP90 client proteins including p-AKT, CDK6, and ERK, and did not induce overexpression of heat shock proteins including HSP70 and HSP90 in MCF-7 cells.	miltefosine	40-51	AKT serine/threonine kinase 1	Homo sapiens	155-158
34406420-7	2021	Western blotting analysis revealed that miltefosine and octenidine significantly down-regulated the expression levels of HSP90 client proteins including p-AKT, CDK6, and ERK, and did not induce overexpression of heat shock proteins including HSP70 and HSP90 in MCF-7 cells.	miltefosine	40-51	cyclin dependent kinase 6	Homo sapiens	160-164
34406420-7	2021	Western blotting analysis revealed that miltefosine and octenidine significantly down-regulated the expression levels of HSP90 client proteins including p-AKT, CDK6, and ERK, and did not induce overexpression of heat shock proteins including HSP70 and HSP90 in MCF-7 cells.	miltefosine	40-51	mitogen-activated protein kinase 1	Homo sapiens	170-173
34406420-9	2021	In conclusion, miltefosine and octenidine could disrupt the molecular chaperone function of HSP90, and thus, their strong and broad-spectrum anticancer activity is at least in part attributed to the inhibition activity against HSP90.	miltefosine	15-26	heat shock protein 90 alpha family class A member 1	Homo sapiens	92-97
34406420-9	2021	In conclusion, miltefosine and octenidine could disrupt the molecular chaperone function of HSP90, and thus, their strong and broad-spectrum anticancer activity is at least in part attributed to the inhibition activity against HSP90.	miltefosine	15-26	heat shock protein 90 alpha family class A member 1	Homo sapiens	227-232